Can a shot replace an IV for myeloma treatment?

NCT ID NCT04045795

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a drug combination (isatuximab, pomalidomide, and dexamethasone) in 56 patients with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to see if giving isatuximab as a shot under the skin works as well as giving it through an IV, and to check safety and side effects. Researchers also looked at how well the treatment controlled the cancer and how patients felt about the shot method.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab (Sarclisa) plus pomalidomide and dexamethasone
What this could lead to: If successful, this could offer a new treatment option for patients with multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 56 participants, so results may not apply to all patients. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

City of Hope Site Number : 8400002

Duarte, California, 91010, United States
Gabrail Cancer Center Site Number : 8400001

Canton, Ohio, 44718, United States
Investigational Site Number : 0360001

Wollongong, New South Wales, 2500, Australia
Investigational Site Number : 0360002

Blacktown, New South Wales, 2148, Australia
Investigational Site Number : 0360003

Richmond, Victoria, 3121, Australia
Investigational Site Number : 0360004

Fitzroy, Victoria, 3065, Australia
Investigational Site Number : 0560001

Leuven, 3000, Belgium
Investigational Site Number : 2500001

Nantes, 44093, France
Investigational Site Number : 2500002

Toulouse, 31059, France
Investigational Site Number : 3920001

Shibuya-ku, Tokyo, 150-8935, Japan
Investigational Site Number : 3920002

Okayama, Okayama-ken, 701-1192, Japan
Investigational Site Number : 7240001

Badalona, Catalunya [Cataluña], 08916, Spain
Investigational Site Number : 7240002

Santander, Cantabria, 39008, Spain
~Banner MD Anderson Cancer Center Site Number : 8400005

Gilbert, Arizona, 85234, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.